

ABSTRACT OF THE DISCLOSURE

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell disorders and in particular, B cell lymphomas. These protocols are based
5 upon the administration of immunologically active mouse/human chimeric anti-CD20 antibodies for the depletion of peripheral blood B cells, including B cells associated with lymphoma.